Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports

References

• Araujo A, Silva MT (2006). The HTLV-1 neurological complex. Lancet Neurol 5:1068–1076.
   PubMed Web of Science ®Google Scholar
• Araujo A, Hall W (2004). Human T-lymphotropic virus type II and neurological disease. Ann Neurol 56:10–19.
   PubMed Web of Science ®Google Scholar
• Blanche P, Diaz E, Gombert B, Sicard D (2000). Devic's neuromyelitis optica and HIV-1 infection [Letters to the Editor]. J Neurol Neurosurg Psychiatry 68:795.
   Google Scholar
• Godoy AJ, Kira J, Hasuo K, Goto I (1995). Characterization of cerebral white matter lesions of HTLV-I-associated myelopathy/tropical spastic paraparesis in comparison with multiple sclerosis and collagen vasculitis: a semiquantitative MRI study. J Neurol Sci 133:102–111.
   Google Scholar
• Harrington WJ Jr, Sheremata W, Hjelle B, Dube DK, Bradshaw P, Foung SK, Snodgrass S, Toedter G, Cabral L, Poiesz B (1993). Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann Neurol 33:411–414.
   PubMed Web of Science ®Google Scholar
• Izumo S, Goto I, Itoyama Y, (1996). Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46:1016–1021.
   PubMed Web of Science ®Google Scholar
• Jacobson S (2002). Immunopathogenesis of human T cell lymphotropic virus type I–associated neurologic disease. J Infect Dis 186(Suppl 2):S187–S192.
   Google Scholar
• Jacobson S, Lehky T, Nishimura M, Robinson S, (1993). Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 33:392–396.
   PubMedGoogle Scholar
• Kasahata N, Shiota J, Miyazawa Y, (2003). Acute human T-lymphotropic virus type 1-associated myelopathy. Arch Neurol 60:873–876.
   Google Scholar
• Kira J, Fujihara K, Itoyama Y, Goto I, Hasuo K (1991). Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci 106:41–49.
   Google Scholar
• Koga M, Takahashi T, Kawai M, Negoro K, Kanda T (2009). Neuromyelitis optica with HTLV-I infection: different from acute progressive HAM? Intern Med 48:1157–1159.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, (2004). A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112.
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Watanabe T, Yamaguchi K, (1992). HTLV-1 uveitis: a distinct clinical entity caused by HTLV-1. Jpn J Cancer Res 83:236–239.
   PubMedGoogle Scholar
• Morgan D, Caskey M, Abbehusen C, (2007). Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP. AIDS Res Hum Retroviruses 23:1499–1504.
   PubMed Web of Science ®Google Scholar
• Morgan OS, Rodgers-Johnson P, Mora C, Char G (1989). HTLV-1 and polymyositis in Jamaica. Lancet 2:1184–1187.
   PubMed Web of Science ®Google Scholar
• Sheremata W, Berger J, Harrington WJ Jr, (1992). Human T lymphotropic virus type I-associated myelopathy. A report of 10 patients born in the United States. Arch Neurol 49:1113–1118.
   Google Scholar
• Takenouchi N, Yao K, Jacobson S (2004). Immunopathogenesis of HTLV-I associated neurological disease: molecular, histopathologic, and immunologic approaches. Frontiers Biosci 9:2527–2539.
   PubMed Web of Science ®Google Scholar
• Umehara F, Nose H, Saito M, (2007). Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I–associated myelopathy. J NeuroVirol 13:260–267.
   Web of Science ®Google Scholar
• Unsong Oh, Yoshihisa Y, Mora C, (2005). Interferon-β1a Therapy in Human T- Lymphotropic Virus type I-associated neurological disease. Ann Neurol 57:526–534.
   Google Scholar
• Vernant JC, Buisson GG, Sobesky G, Arfi S, Gervaise G, Roman GC (1987). Can HTLV-1 lead to immunological disease [letter]? Lancet 2:404.
   Google Scholar
• Wingerchuk DM (2006). Neuromyelitis optica. Int MS J 13:42–50.
   PubMedGoogle Scholar
• Wingerchuk DM (2007). Diagnosis and treatment of neuromyelitis optica. Neurologist 13:2–11.
   PubMedGoogle Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007). The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG (2008). Neuromyelitis optica. Curr Treat Options Neurology 10:55–66.
   PubMed Web of Science ®Google Scholar